Navigation Links
Oncothyreon reports third quarter 2009 financial results & provides product pipeline update
Date:11/11/2009

l of cancer cells. Oncothyreon currently expects to complete patient enrollment in its Phase 1 trial of PX-478 in the fourth quarter of 2009. In addition, pre-clinical data concerning the activity of PX-478 in diffuse large B-cell lymphoma cells will be presented at the American Society of Hematology meeting in early December 2009.

Conference Call and Webcast

Oncothyreon's management will discuss the Company's third quarter 2009 financial results and provide a business update during a conference call beginning at 4:30 p.m. ET/1:30 p.m. PT today, Wednesday, November 11, 2009. To listen to a webcast of the discussion, visit www.oncothyreon.com.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.

Forward-Looking Statements

In order to provide Oncothyreon's investors with an understanding of our current results and future prospects, this release may contain statements that are forward-looking. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, the following: our expectations regarding future expenses; clinical and pre-clinical development activities, including our plans to substantially complete the pre-clinical development of BGLP40 in 2010, our goal to initiate c
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Oncothyreon announces webcast of third quarter 2009 financial results conference call
2. Oncothyreon announces appointment of Douglas E. Williams, Ph.D., to board of directors
3. Oncothyreon to present at Rodman Renshaw Global Healthcare Conference
4. Oncothyreon reports second quarter 2009 financial results
5. Oncothyreon announces closing of $15.0 million registered direct financing
6. Oncothyreon announces webcast of second quarter 2009 financial results conference call
7. Oncothyreon appoints Diana Hausman as Vice President of Clinical Development
8. Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer
9. Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer
10. Oncothyreon appoints Scott Peterson as Vice President of Research and Development
11. Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , 25 novembre 2014 Theravalues Corporation est ... le marché européen au salon Hi Europe 2014 ... ). Curcumine la plus biodisponible ... amorphe (non-cristalline) à des ingrédients approuvés par les ... pigment jaune présent dans la racine de curcuma ...
(Date:11/26/2014)...  Roka Bioscience, Inc. (NASDAQ: ROKA ), a ... the detection of foodborne pathogens, today announced that Paul ... th Annual Healthcare Conference on December 2, 2014 at ... York Palace in New York, NY . ... Company, its operations, strategies and prospects may be discussed. To ...
(Date:11/24/2014)... 2014  Last week, Representatives Gus Bilirakis ... took a bold bipartisan step on behalf of ... Act. Original co-sponsors of the legislation include Representatives ... incentivize drug makers and innovators to "repurpose" major ... cancers, which opens the door to the development ...
(Date:11/24/2014)...   Veracyte, Inc. (Nasdaq: VCYT ) ... chief executive officer, will present in a fireside chat discussion ... on Tuesday, December 2, 2014 at 12:30 p.m. ET in ... audio webcast and subsequent replay may be accessed by visiting ... website at least 15 minutes prior to the live webcast ...
Breaking Biology Technology:La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3Roka Bioscience to Present at the Piper Jaffray Healthcare Conference 2OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2Veracyte to Present at the Piper Jaffray 26th Annual Healthcare Conference 2
... BETHESDA, Md., Sept. 16 American Capital Ltd. ... 15, it completed the sale of its portfolio company Axygen ... Inc., to Corning Incorporated for approximately $400 million. The ... fee income, from the equity invested by American Capital,s affiliated ...
... , , COLUMBIA, Md., Sept. 16 Martek ... David M. Pernock to its Board of Directors. , ... extensive background in the commercialization of pharmaceutical products, having served from ... (GSK), one of the world,s leading healthcare companies. In his most ...
... HEIDELBERG, Germany, September 16 , ... Drug Targets in Wnt Pathway , ... antagonizes Wnt signalling"** is now available online in,Nature. , ... proteomics,platform was used to identify a small molecule which plays ...
Cached Biology Technology:American Capital Receives $182 Million In Proceeds From Sale of Axygen Bioscience 2American Capital Receives $182 Million In Proceeds From Sale of Axygen Bioscience 3American Capital Receives $182 Million In Proceeds From Sale of Axygen Bioscience 4Martek Announces Addition to Its Board of Directors 2Cellzome Technology Used to Unravel Novel Regulatory Mechanism in Cancer Signaling Pathway 2
(Date:11/10/2014)... began appearing on U.S. store shelves in early 2010, ... since. The small packets can be tossed into a ... liquid or powder. The convenience, though, has come with ... researchers at Nationwide Children,s Hospital found that from 2012 ... 17,230 children younger than 6 years of age swallowing, ...
(Date:11/7/2014)... 2014  In conjunction with the Glendale ... Community Foundation of the Verdugos has announced the " ... a $250,000 initiative to keep the Verdugo Regional Crime Lab ... six months of existence, the Lab has processed more than ... law enforcement. "Because our number one priority is ...
(Date:11/6/2014)... Fla. -- A groundbreaking paper from a team of ... understanding of how plants could adapt to and survive ... research, published in the latest issue of the journal ... chromatin (the complex of DNA and proteins) is organized ... so that some genes are turned on and others ...
Breaking Biology News(10 mins):Study finds laundry detergent pods, serious poisoning risk for children 2Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Maize analysis yields whole new world of genetic science 2
... the Center for the Neural Basis of Cognition (CNBC), ... University of Pittsburgh, have for the first time described ... are rewired on the fly allowing stimuli to be ... a paper in the January 2008 issue of Nature ...
... Suppressing a cellular cleanup-mechanism known as autophagy can accelerate ... degeneration. In an upcoming issue of Autophagy, scientists at ... first time that the opposite is true as well: ... prevented the age-dependent accumulation of cellular damage in neurons ...
... appear to have been influenced by RNA polymerase II. ... DNA into messenger-RNA (mRNA), which in turn is the ... is highly conserved through evolution, with many of its ... Single-cell organisms were already in existence 500 million ...
Cached Biology News:Neuronal circuits able to rewire on the fly to sharpen senses 2Aging gracefully requires taking out the trash 2Aging gracefully requires taking out the trash 3Evolution with a restricted number of genes 2